This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Brain glioblastoma and astrocytoma
C3_GBM_ASTROCYTOMA
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions
HLP_C3_GBM
or HLP_C3_ASTROCYTOMA
355
Check pre-conditions, main-only, mode, registry filters
Cause of death: ICD-10
C71
Cause of death: ICD-9
191
Cause of death: ICD-8
191
Cancer registry: Topography ICD-O-3
C71
Cancer registry: Morphology ICD-O-3
9400|9440
Cancer registry: Behaviour codes
3
2 out of 7 registries used, show all original rules.
355
Check minimum number of events None
355
Remove individuals based on genotype QC
327
C3_GBM_ASTROCYTOMA
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Brain glioblastoma and astrocytoma
based on the number of shared cases.
Broader endpoints:
- Brain glioblastoma and astrocytoma (controls excluding all cancers)
- Malignant neoplasm of brain (controls excluding all cancers)
- Malignant neoplasm of brain
- Malignant neoplasm of eye, brain and central nervous system (controls excluding all cancers)
- Malignant neoplasm of eye, brain and central nervous system
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 327 | 124 | 203 |
| Unadjusted prevalence (%) | 0.09 | 0.06 | 0.12 |
| Mean age at first event (years) | 58.56 | 58.17 | 58.80 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_GBM_ASTROCYTOMA – Brain glioblastoma and astrocytoma
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Brain glioblastoma and astrocytoma
↥Endpoint not on priority list, no data to show.